NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-07-23
Reading SGRY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The current thesis state is intact, supported by recent strong financial performance, but it faces risks that could impact future results.
The market seems to have priced in a stretched valuation compared to peers, indicating that expectations are relatively high. There is a notable expectations gap, suggesting that investors might anticipate continued improvement in performance.
Management is focused on achieving specific financial targets, including Adjusted EBITDA and revenue guidance for 2026. Recent results show steady growth, but the company remains loss-making, which adds uncertainty to its fundamentals.
The thesis hinges on the performance of sector bellwethers like HCA, THC, and DVA. If these companies continue to perform well, it could support SGRY's growth. Conversely, any negative guidance from these peers could pose risks to SGRY's momentum.
Overall, SGRY's prospects are tied to both its execution on financial targets and the broader healthcare sector's performance. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will provide insight into revenue, cash flow, and EBITDA progress.
Confirms one read:Earnings report shows positive trends in revenue and cash flow.
Confirms the other:Earnings report reveals continued declines in revenue and cash flow.
Why it matters: If health care sector growth speeds up, it could boost Surgery Partners' performance.
Confirms:Health care sector revenue growth is speeding up to over 10% each year.
Disproves:Sector revenue growth continues to slow below 8% year over year.
Why it matters: This is crucial to stay on track for the $3.35B to $3.45B guidance for 2026.
Confirms:Q2 revenue was $850M or more. This shows sales are recovering.
Disproves:Q2 revenue was below $800M. This shows sales are still declining.
Why it matters: The company aims for $3.35B to $3.45B in revenue for 2026. Any change signals progress or challenges.
Confirms:Revenue guidance remains unchanged or is raised during the Q2 earnings call on August 4.
Disproves:Revenue guidance is lowered during the Q2 earnings call.
Why it matters: Earnings results will show how Surgery Partners is doing financially and what to expect.
Confirms one read:Earnings report shows revenue growth above 5% year over year.
Confirms the other:Earnings report shows revenue decline year over year.
Why it matters: This is key to achieving the $530M target for the year and signals operational strength.
Confirms:Q2 Adjusted EBITDA was $130M or more. This supports the yearly goal.
Disproves:Q2 Adjusted EBITDA was below $100M. This shows there are operational challenges.
Why it matters: This sale could bring in a lot of cash. It will help Surgery Partners grow.
Confirms:The deal will close after getting all approvals. It will bring in about $795 million.
Disproves:The transaction fails to close due to lack of required approvals or other conditions.
Why it matters: Better cash flow from operations is key for Surgery Partners' financial health.
Confirms:Cash from operations is over $11.7 million. This shows ongoing improvement.
Disproves:Cash from operations is below $11.7 million. This suggests possible cash flow problems.
